Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think!

Elsevier
Publish with us

See Elsevier at Pharma Meets AI 2026

Connect with Elsevier’s experts to explore how trusted scientific content, structured data, and responsible AI can accelerate drug development and strengthen your AI strategy in pharma R&D.

Schedule meeting
A female scientist conducting research on a sample though a microscope in a pharmaceutical laboratory

Join Elsevier’s conference keynote presentation

Time: April 20 | 16:40–16:55

Presenter: Elliott Parris MSci, Advanced Data Solutions Manager, Elsevier

Title: From Pilot to Production: Building Trust in Agentic AI for Pharma R&D

AI is already everywhere in pharma R&D. Trust is not. While 84% of researchers use AI, only 22% trust it. Elliott Parris explores the 3 phases behind trustworthy AI: building the data foundation, embedding AI into workflows, and enabling more integrated, agentic experiences through tools like LeapSpace. Using real pharma examples and live audience interaction, he shows why evidence quality, workflow fit, governance, and rights are what separate pilots that impress from systems people can actually trust.

Elsevier as trusted partner

Elsevier partners with pharmaceutical and life sciences organizations worldwide to transform high-quality scientific information into actionable insights.

Our AI-enabled platforms and data-driven solutions support every stage of drug development — from early discovery and translational research to clinical development and regulatory submission — helping teams reduce uncertainty and make confident decisions.

Pharma organizations rely on Elsevier to:

  • Identify emerging mechanisms, biomarkers, and therapeutic opportunities grounded in validated evidence

  • Strengthen R&D portfolio planning with data-driven insights

  • Accelerate research cycles through faster access to literature, competitive intelligence, and safety data

  • Reduce development and compliance risk by learning from past successes, failures, and safety signals

The result: research teams spend less time searching and reconciling fragmented information — and more time advancing innovation.

Pharma Solutions

Elsevier provides integrated scientific, biomedical, and chemistry intelligence to support better drug discovery and development outcomes.

Explore full-text research on ScienceDirect, the leading database of peer-reviewed scientific, technical and health literature. Accelerate drug discovery with Reaxys, a database combining over a billion chemistry data points with AI.

Conduct targeted biomedical literature searches with Embase, the premier biomedical literature database.

Identify research trends and track KOLs with the 2.4 billion cited references in Scopus.

Visualize biological relationships and filter by biological concepts with EmBiology.

Find drug safety, efficacy and DMPK data and complete approval packages with PharmaPendium.

Most of these solutions include AI tools to help R&D teams research more efficiently and innovate with confidence. Together, these platforms and tools provide the structured evidence foundation needed to support scientific rigor, strategic decision-making, and regulatory compliance.

Data Solutions

One of the biggest challenges R&D-intensive companies face is to quickly and reliably extract meaning from a vast and growing sea of scientific data. Discover a range of solutions to help you transform data into discoveries.

  • Power your custom applications and third-party tools with domain-specific curated and enriched

    Datasets

  • Get more from your data with text analytics and data enrichment tools from

    SciBite

  • Solve data integration and applied analytics challenges with support from the domain and data science experts on our Professional Services team

LeapSpace AI workspace

Leapspace for Industry - header

LeapSpace is Elsevier's new research-grade AI workspace launched in January 2026.

LeapSpace is Elsevier’s next-generation AI-assisted workspace that delivers publisher-neutral insights to help researchers move faster from ideation to impact while safeguarding research integrity, transparency and trust. Developed in collaboration with the research community, it integrates trusted full text and abstracts with advanced AI capabilities.

LeapSpace supports workflows such as:

  • Literature analysis and synthesis

  • Hypothesis generation

  • Cross-domain exploration

  • Complex research and evidence mapping

Meet Our Experts

Meet with Elsevier’s experts to discuss your priorities, whether that’s AI-driven drug discovery, clinical development, regulatory strategy, or enterprise-wide digital transformation.

Book a one-on-one meeting to explore how trusted data, AI-powered tools, and deep domain expertise can help your teams make smarter decisions and deliver greater impact.

Meet Rosa Ambrosio

Rosa Ambrosio LinkedIn

Key Account Manager, Pharma & Biotech

Consultant in Embase, Reaxys, PharmaPendium, ScienceDirect, and Scopus (South Europe) [email protected]